Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
With the prospect of cheaper semaglutide via compounders vanishing, there's been some good news on the affordability front for GLP1s – Novo Nordisk is lowering prices on their direct-to-consumer cash-first offering to $499/month.
While this doesn't help those who can't pay out of pocket (insurers still actively avoid covering GLP1s, and MSRP via other distributors), those who can afford to spare $499/month can access Wegovy via the "savings program"
NOVO NORDISK INC.
Want to read more of our analysis along with what customers paid before and eligibility news? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
